GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BioTelemetry Inc (NAS:BEAT) » Definitions » Asset Turnover

BioTelemetry (BioTelemetry) Asset Turnover : 0.16 (As of Sep. 2020)


View and export this data going back to 2008. Start your Free Trial

What is BioTelemetry Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. BioTelemetry's Revenue for the three months ended in Sep. 2020 was $114.7 Mil. BioTelemetry's Total Assets for the quarter that ended in Sep. 2020 was $723.4 Mil. Therefore, BioTelemetry's Asset Turnover for the quarter that ended in Sep. 2020 was 0.16.

Asset Turnover is linked to ROE % through Du Pont Formula. BioTelemetry's annualized ROE % for the quarter that ended in Sep. 2020 was 6.88%. It is also linked to ROA % through Du Pont Formula. BioTelemetry's annualized ROA % for the quarter that ended in Sep. 2020 was 3.71%.


BioTelemetry Asset Turnover Historical Data

The historical data trend for BioTelemetry's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioTelemetry Asset Turnover Chart

BioTelemetry Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.44 1.29 0.79 0.72 0.69

BioTelemetry Quarterly Data
Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.17 0.17 0.16 0.14 0.16

Competitive Comparison of BioTelemetry's Asset Turnover

For the Diagnostics & Research subindustry, BioTelemetry's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioTelemetry's Asset Turnover Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, BioTelemetry's Asset Turnover distribution charts can be found below:

* The bar in red indicates where BioTelemetry's Asset Turnover falls into.



BioTelemetry Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

BioTelemetry's Asset Turnover for the fiscal year that ended in Dec. 2019 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2019 )/( (Total Assets (A: Dec. 2018 )+Total Assets (A: Dec. 2019 ))/ count )
=439.107/( (586.801+685.72)/ 2 )
=439.107/636.2605
=0.69

BioTelemetry's Asset Turnover for the quarter that ended in Sep. 2020 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Sep. 2020 )/( (Total Assets (Q: Jun. 2020 )+Total Assets (Q: Sep. 2020 ))/ count )
=114.655/( (709.657+737.095)/ 2 )
=114.655/723.376
=0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


BioTelemetry  (NAS:BEAT) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

BioTelemetry's annulized ROE % for the quarter that ended in Sep. 2020 is

ROE %**(Q: Sep. 2020 )
=Net Income/Total Stockholders Equity
=26.856/390.1045
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(26.856 / 458.62)*(458.62 / 723.376)*(723.376/ 390.1045)
=Net Margin %*Asset Turnover*Equity Multiplier
=5.86 %*0.634*1.8543
=ROA %*Equity Multiplier
=3.71 %*1.8543
=6.88 %

Note: The Net Income data used here is four times the quarterly (Sep. 2020) net income data. The Revenue data used here is four times the quarterly (Sep. 2020) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

BioTelemetry's annulized ROA % for the quarter that ended in Sep. 2020 is

ROA %(Q: Sep. 2020 )
=Net Income/Total Assets
=26.856/723.376
=(Net Income / Revenue)*(Revenue / Total Assets)
=(26.856 / 458.62)*(458.62 / 723.376)
=Net Margin %*Asset Turnover
=5.86 %*0.634
=3.71 %

Note: The Net Income data used here is four times the quarterly (Sep. 2020) net income data. The Revenue data used here is four times the quarterly (Sep. 2020) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


BioTelemetry Asset Turnover Related Terms

Thank you for viewing the detailed overview of BioTelemetry's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


BioTelemetry (BioTelemetry) Business Description

Traded in Other Exchanges
N/A
Address
1000 Cedar Hollow Road, Suite 102, Malvern, PA, USA, 19355
BioTelemetry Inc provides monitoring services and digital population health management for healthcare providers, medical device manufacturing, and centralized core laboratory services for clinical research. It operates under healthcare, technology, and research segments. The Healthcare segment is focused on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders. The Research segment is engaged in central core laboratory services providing cardiac monitoring, imaging services, scientific consulting and data management services for drug and medical device trials and the Technology segment, focuses on the development, manufacturing, testing, and marketing of cardiovascular and blood glucose monitoring devices to medical companies, clinics and hospitals.
Executives
Kirk E Gorman director 367 SOUTH GULPH ROAD, KING PRUSSIA PA 19406
Stephen Rietiker director C/O BIOTELEMETRY, INC., 1000 CEDAR HOLLOW RD. SUITE 102, MALVERN PA 19355
Tiffany Olson director C/O CASTLE BIOSCIENCES, INC., 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD TX 77546
Joseph A. Frick director ONE COMMERCE SQUARE 2005 MARKET ST., SUITE 3300 19103 PR 19073
Laura N. Dietch director 1000 CEDAR HOLLOW RD. SUITE 102 MALVERN PA 19355
Anthony James Conti director 76 GOLFVIEW DRIVE, IVYLAND PA 18974
Rebecca W Rimel director 345 PARK AVENUE, NEW YORK NY 10154
Robert J. Rubin director 7901 SPRINGER ROAD, BETHESDA MD 20817
Hill Colin director 196 BROADWAY CAMBRIDGE MA 02139
Andrei G Stoica officer: SVP & CTO 1000 CEDAR HOLLOW ROAD, MALVERN PA 19355
Joseph H Capper director, officer: President & CEO BIOTELEMETRY, INC., 1000 CEDAR HOLLOW ROAD, #102, MALVERN PA 19355
Manish Wadhwa officer: SVP & CMO 1000 CEDAR HOLLOW ROAD MALVERN PA 19355
Fred Broadway officer: President BioTel Heart BIOTELEMETRY, INC. 1000 CEDAR HOLLOW ROAD, #102 MALVERN PA 19355
Daniel Wisniewski officer: SVP, Technical Operations BIOTELEMETRY, INC. 1000 CEDAR HOLLOW ROAD, #102 MALVERN PA 19355
Heather C Getz officer: EVP, CFO & CAO BIOTELEMETRY, INC., 1000 CEDAR HOLLOW ROAD, #102, MALVERN PA 19355